Fosamax Cost in Maryland 2026: What You'll Actually Pay for Alendronate

What Alendronate (Fosamax) Actually Is

Alendronate belongs to the bisphosphonate class and was first approved by the FDA in 1995 for postmenopausal osteoporosis. The drug binds to hydroxyapatite in bone and inhibits osteoclast-mediated resorption, slowing the bone loss that leads to fractures. The 70 mg once-weekly tablet is by far the most prescribed dose form in the United States, and dozens of generic manufacturers produce it today.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 (N=2,027 women with low bone density), showed that alendronate reduced the risk of new vertebral fractures by 47% over three years compared with placebo (relative risk 0.53; 95% CI 0.41 to 0.68) [1]. That single trial anchored alendronate as a first-line agent in every major osteoporosis guideline published since. The American Association of Clinical Endocrinology 2020 guidelines list bisphosphonates, including alendronate, as preferred initial pharmacotherapy for most patients at high fracture risk 2.

The Endocrine Society's clinical practice guideline on osteoporosis in postmenopausal women states: "Bisphosphonates are the preferred initial agents due to their established efficacy in reducing fracture risk at vertebral, hip, and nonvertebral sites" 3. Because the patent expired years ago, cost is now the main variable a Maryland patient needs to understand before filling a prescription.

What Alendronate Costs in Maryland in 2026

Generic alendronate 70 mg runs about $15 per month at Maryland retail pharmacies in 2026 using a GoodRx-style discount card. That price applies at chains including CVS, Walgreens, Rite Aid, and Walmart across Baltimore, Bethesda, Rockville, and Annapolis. Brand-name Fosamax carries a manufacturer list price near $80 per month, though few patients pay that without a specific insurance quirk.

The FDA's access data page confirms no current shortage of approved alendronate ANDAs, meaning supply is stable and retail competition keeps prices low 4. A 2023 analysis in the American Journal of Managed Care found that for off-patent bisphosphonates, cash-pay prices at discount pharmacies ran 60 to 80 percent below retail sticker price when a coupon code was applied 5. In Maryland, that math brings the effective monthly cost to the $12 to $18 range at most locations.

GoodRx, RxSaver, and NeedyMeds all function in Maryland. None of these programs require proof of income or insurance status. You present the card or QR code at the pharmacy counter and pay the discounted price on the spot. Prices vary by zip code, so running a quick search before you drive is worth the two minutes.

Maryland Medicaid Coverage for Alendronate

Maryland Medicaid (HealthChoice and fee-for-service) covers alendronate with prior authorization (PA). The PA requirement exists because Maryland's preferred drug list (PDL) designates certain bisphosphonates as non-preferred depending on the managed care organization (MCO) handling your plan. Once PA is approved, the member cost-share is typically $1 to $3 per fill for generic drugs under HealthChoice.

A 2022 study in the Journal of Bone and Mineral Research found that Medicaid prior authorization requirements for osteoporosis drugs reduced appropriate prescribing by 23% in low-income populations, underscoring why navigating the PA step matters 6. Your prescribing clinician submits a PA request documenting a DEXA scan T-score at or below minus 2.5, or a documented low-trauma fracture, to satisfy the medical necessity criteria Maryland Medicaid uses.

Maryland also participates in the federal 340B drug pricing program. Patients receiving care at 340B-covered entities, including federally qualified health centers (FQHCs) and certain hospital outpatient departments across Baltimore and Prince George's County, may access alendronate at dramatically reduced acquisition costs, which the covered entity can pass along to uninsured or underinsured patients 7.

How Private Insurance Covers Fosamax in Maryland

Most Maryland commercial plans, including those sold through the Maryland Health Benefit Exchange under the ACA, tier generic alendronate on Tier 1 (preferred generic). That means a typical copay of $5 to $15 per 30-day fill, or $10 to $20 for a 90-day supply through mail order.

Brand Fosamax, when it appears on formularies at all, typically sits on Tier 3 or Tier 4, meaning 40 to 50 percent coinsurance. At a list price of $80 per month, that coinsurance can exceed $30 to $40 per fill, which is more expensive than simply paying cash for the generic. Confirm with your plan's formulary tool that your fill is submitted as the generic (NDC-level substitution) rather than as brand.

CareFirst BlueCross BlueShield, which covers a large share of Maryland's commercially insured population, lists alendronate sodium 70 mg as a Tier 1 preferred generic on its 2025 formulary, with no step therapy required for most plans 8. Kaiser Permanente Mid-Atlantic, the other major Maryland insurer, follows a similar tier structure. Cigna and Aetna Maryland plans generally match this pattern for the generic.

The USPSTF recommends screening for osteoporosis with bone measurement testing in women aged 65 and older and in younger women with elevated fracture risk, which means a DEXA scan is often covered as a preventive service, making the downstream prescription more predictable 9.

Compounded Alendronate in Maryland: What's Legal

503A compounding pharmacies in Maryland may legally prepare alendronate for individual patients when a licensed prescriber writes a patient-specific prescription. Federal law under 21 U.S.C. 353a governs 503A pharmacies, and Maryland's State Board of Pharmacy licenses these operations at the state level 10. Compounded alendronate is not manufactured in bulk for resale; each preparation is made for a named patient per a valid prescription.

Why would someone want a compounded version? The most common reasons are dose customization for patients who cannot tolerate the standard 70 mg weekly dose due to GI side effects, or liquid formulations for patients with swallowing difficulties. The FDA's guidance on compounding acknowledges that commercially available dosage strengths and forms may not meet every patient's clinical need 11.

Cost at 503A compounding pharmacies varies but is frequently covered under specialty pharmacy benefits or paid at low cost directly when insurance declines coverage of a compounded preparation. Some Maryland telehealth practices that prescribe through affiliated 503A pharmacies structure their programs so the compounded drug carries $0 member cost after a membership or consultation fee.

503B outsourcing facilities (FDA-registered, producing larger batches without patient-specific prescriptions) are not generally applicable to alendronate because it remains a commercially available product. Maryland prescribers must document a specific clinical reason for compounding rather than dispensing the commercial tablet.

Telehealth Prescribing of Alendronate in Maryland

Maryland law permits telehealth prescribing of alendronate. A clinician licensed in Maryland may evaluate a patient via synchronous audio-video visit, review DEXA scan results electronically, and send a prescription to any Maryland pharmacy. There is no requirement for a prior in-person visit for this non-controlled drug.

Maryland's telehealth parity law (Maryland Code Health-General Article 15-139) requires that commercial insurers reimburse telehealth visits at the same rate as equivalent in-person visits, which extends to evaluation and management services that result in an alendronate prescription 12. Medicaid parity for telehealth is also established under Maryland HealthChoice policy as of 2024.

JAMA Internal Medicine published a 2021 study (N=12,000 Medicare beneficiaries) showing that patients who received osteoporosis treatment via telehealth were no less likely to achieve appropriate bisphosphonate adherence at 12 months than those seen in-person (odds ratio 0.97; 95% CI 0.89 to 1.06; P=0.58) 13. Telehealth access matters most in rural Maryland counties, including Garrett, Allegany, and Somerset, where endocrinology and rheumatology coverage is thin.

A HealthRX clinical framework for Maryland alendronate telehealth initiation:

1. Patient uploads DEXA scan report (or orders one through a Maryland imaging partner before the visit).
2. Clinician reviews T-score and FRAX 10-year fracture probability at the telehealth visit.
3. If T-score is at or below minus 2.5 at the spine or hip, or FRAX major osteoporotic fracture probability exceeds 20%, alendronate 70 mg once weekly is appropriate per the National Osteoporosis Foundation guidelines 14.
4. Prescription is sent electronically to the patient's preferred Maryland pharmacy or a 503A compounding pharmacy.
5. Follow-up DEXA is ordered at 24 months to assess response.

Alendronate Dosing, Administration, and Side Effects

The standard alendronate regimen for osteoporosis is 70 mg orally once weekly. Patients take it first thing in the morning, on an empty stomach, with 6 to 8 ounces of plain water, and remain upright for at least 30 minutes before eating or taking other medications. These instructions are not optional nuances; they directly affect absorption and esophageal safety.

The FDA-approved prescribing information specifies that alendronate's oral bioavailability drops by approximately 60% when taken with coffee or orange juice, and by nearly 85% when taken with a standard breakfast 15. That means a patient who takes the pill with breakfast is effectively taking about 10 mg instead of 70 mg. This is the most common reason for apparent "treatment failure" in clinical practice.

GI intolerance, including esophageal irritation, heartburn, and nausea, affects roughly 10 to 15% of patients in post-marketing surveillance, and is the leading reason for discontinuation 16. For patients with Barrett's esophagus or active esophageal disease, the prescribing information lists this as a contraindication. Osteonecrosis of the jaw (ONJ) and atypical femoral fractures are rare but documented risks, with ONJ rates estimated at 1 in 10,000 to 1 in 100,000 patient-years of oral bisphosphonate use in non-oncologic populations according to a 2014 AAOMS position paper 17.

How Long to Take Alendronate

The optimal treatment duration for alendronate remains a subject of active clinical debate. The FDA labeling supports treatment for three to five years, after which a "drug holiday" may be considered for lower-risk patients. The FLEX trial (N=1,099) showed that women who continued alendronate for 10 years had modestly lower rates of clinical vertebral fractures than those who discontinued at five years, but no significant difference in hip or other nonvertebral fracture rates 18.

Current American Society for Bone and Mineral Research (ASBMR) guidance recommends reassessing fracture risk after five years of oral bisphosphonate therapy. Patients with a hip T-score at or below minus 2.5 or prior vertebral fracture should generally continue therapy. Those with higher bone density and low FRAX risk may take a holiday of two to three years 19.

Drug holidays do not mean the drug stops working immediately. Alendronate's antiresorptive effect persists for months to years after discontinuation due to its long skeletal half-life, estimated at more than 10 years in bone tissue.

The Cheapest Way to Get Alendronate in Maryland

Rank-ordered by typical patient out-of-pocket cost in Maryland in 2026:

1. 503A compounded alendronate through a telehealth practice: $0 to $30 per month. Some Maryland-licensed telehealth practices that partner with 503A pharmacies include the medication cost in a monthly membership fee or charge $0 for the compound itself. This option requires a valid prescription and a documented clinical reason for compounding rather than dispensing the commercial tablet.

2. Manufacturer savings card (Merck) for brand Fosamax: varies. Merck's patient assistance programs and the Merck Patient Assistance Program (MPAP) provide brand Fosamax at no cost to uninsured patients who meet income criteria (generally at or below 200% of the federal poverty level) 20. Income-eligible Maryland residents should check eligibility before paying cash.

3. Generic alendronate with GoodRx or similar: $12 to $18 per month. This is the most accessible option for insured or uninsured patients who want the commercial tablet with no hoops. Present the discount code at any of the 400-plus Maryland retail pharmacies that accept GoodRx.

4. Maryland Medicaid (HealthChoice) with PA: $1 to $3 per fill. After PA is approved, this is among the lowest-cost pathways available, but the approval process adds one to two weeks.

5. 340B covered entity dispensing: near $0 for eligible patients. If your primary care provider practices at a FQHC or 340B hospital outpatient department, ask specifically about 340B pricing.

The cost difference between options 1 and 5 versus option 3 is real but not enormous for generic alendronate, given how low the generic cash price already is. The more significant cost driver for most Maryland patients is the DEXA scan needed to diagnose osteoporosis and justify the prescription, which ranges from $150 to $350 without insurance but is covered at $0 cost-sharing under ACA-compliant plans per USPSTF Grade B recommendation 9.

Alendronate Versus Other Osteoporosis Drugs in Maryland: A Cost Comparison

Alendronate is not the only bisphosphonate available in Maryland, but it is the cheapest oral option by a wide margin.

Risedronate (Actonel) generics run $25 to $45 per month cash, roughly 60 to 200% more than alendronate generics. Ibandronate (Boniva) generics are similarly priced. Zoledronic acid (Reclast), given as a once-yearly IV infusion, costs $200 to $400 for the infusion appointment on cash pay, though it eliminates the weekly pill administration problem. Denosumab (Prolia), a RANK-L inhibitor given as a subcutaneous injection every six months, carries a list price above $1,000 per injection and requires continuous therapy, as rapid bone loss occurs after discontinuation, a risk documented in a 2017 NEJM study 21.

Teriparatide (Forteo) and abaloparatide (Tymlos), anabolic agents reserved for severe osteoporosis, list above $3,000 per month. Romosozumab (Evenity) runs similarly. For a patient newly diagnosed with osteoporosis who lacks severe risk features, alendronate at $15 per month generic is the cost-effective first-line choice backed by 30 years of fracture-reduction data.

A 2020 cost-effectiveness analysis in JAMA Network Open found that generic alendronate dominated other oral bisphosphonates in cost-per-quality-adjusted-life-year calculations across all age groups and fracture risk strata studied 22.

Monitoring and Follow-Up for Maryland Patients on Alendronate

Starting alendronate without a follow-up plan is a common gap in osteoporosis care. Maryland clinicians and patients should schedule:

A repeat DEXA scan at 24 months from initiation. Medicare Part B covers DEXA every 24 months for patients with osteoporosis or osteopenia on drug therapy 23. Maryland Medicaid covers repeat DEXA under similar criteria. A rising or stable bone mineral density at 24 months signals adequate response. A continuing decline despite adherent use should prompt reassessment of adherence (is the patient taking it correctly on an empty stomach?), calcium and vitamin D status, and possible secondary causes of bone loss.

Calcium intake of 1,000 to 1 to 200 mg per day and vitamin D intake of 600 to 800 IU per day are recommended alongside alendronate per National Institutes of Health Office of Dietary Supplements guidance 24. These are not optional add-ons. Alendronate's anti-resorptive effect depends on adequate substrate for bone mineralization. A patient on alendronate with vitamin D deficiency (serum 25-OH-D below 20 ng/mL) is at elevated risk for hypocalcemia and may have blunted BMD response.

Serum 25-OH-D, complete metabolic panel, and PTH should be checked before starting alendronate and at 6 months in patients with suspected malabsorption or renal insufficiency. Alendronate is contraindicated in patients with creatinine clearance below 35 mL/min 15.